HC Wainwright & Co. reiterated coverage on Agenus with a new price target
$AGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
HC Wainwright & Co. reiterated coverage of Agenus with a rating of Buy and set a new price target of $14.00 from $12.00 previously